Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease

DARIDOR-ALZ is a phase IV clinical trial designed to evaluate both the efficacy and safety of daridorexant, a selective dual orexin receptor antagonist that blocks the actions of the orexin neuropeptides at both orexin-1 and orexin-2 receptors, in selected populations of MCI and mild-to-moderate AD patients with insomnia complaints.

NCT Number	NCT05924425
Lead Sponsor	University Hospital, Montpellier Collaborators: Idorsia Pharmaceuticals Ltd.
Conditions	Alzheimer Disease, Insomnia Disorder, Sleep
Enrollment	62 participants
Start Date	2024-03-13
Primary Completion	2027-05-13 (estimated)
Study Completion	2028-03-13 (estimated)
Updated on ClinicalTrials.gov	2026-06-25